Domestic specific drugs are approved orally, and two tablets can take effect. COVID-19's small molecule drug VV 1 16 has entered the clinical trial stage in China. Small molecule drug VV 1 16 is being promoted to China, and two tablets will take effect after the approval of specific oral drugs in China.
According to media reports, there is good news in China. The specific drug VV 1 16 developed by China for COVID-19 has been approved for marketing, and oral administration should be effective, which means that the global epidemic of COVID-19 is expected to end.
COVID-19 swept the world.
It has been two years since the COVID-19 outbreak. With the passage of time, COVID-19 did not disappear by itself as originally expected. On the contrary, it is getting worse and worse, and even mutates into a variety of strains, of which Omicron strain is the most popular one now.
Under the terror of Omicron, China gradually controlled the domestic epidemic by virtue of its institutional advantages. But not all countries are as lucky as China. Under COVID-19's offensive, the number of people who died in the new crown in the United States has exceeded 930,000, and the number of people diagnosed in some countries in a single day has exceeded 654.38 million+.
China invented a specific medicine.
China has been developing specific drugs since the epidemic situation stabilized. Thanks to the unremitting efforts of scientific researchers, China has developed the specific medicine VV 1 16 against COVID-19. Clinical data show that two tablets can obviously see the effect. Today, this special drug has been approved by the Uzbek government. Compared with the previous macromolecular drugs, the specific drug developed this time is a small molecular oral drug. The advantage of this specific medicine is not only to save production cost, but also to facilitate transportation and storage. This means that the era under COVID-19 is expected to end.
Oral medicine VV 1 16 has obvious effect.
Before VV 1 16 came out, Remdesivir had the most remarkable effect on COVID-19. Its working principle is to destroy the replication of the virus to curb the spread of the virus, but after evaluation, Remdesivir will also bring serious side effects to the host while fighting the virus. Inspired by Redixivir, VV 1 16 improved on the basis of Redixivir, and solved the side effects caused by drug action. VV 1 16 can also be taken orally to make the drug take effect quickly in the body. In clinical trials, the researchers applied VV 1 16 to mice infected with the virus, which significantly improved the pathological changes of lung tissue.
In fact, most of the confirmed cases in COVID-19 are mild and moderate infections. If they take VV 1 16 orally like a cold to cure COVID-19, it will be of great significance for global epidemic prevention and control. You know, oral drugs can reduce the risk of infection and save medical expenses. In addition to the research and development of VV 1 16, other oral drugs being developed in China are also expected to be listed. I have to say that the remarkable function of VV 1 16 has made people who are fighting against COVID-19 virus see the dawn of hope.
Domestic specific drugs are approved orally, and two tablets will be effective. 2 People's Daily Health Client combed and summarized the drugs that have been approved for marketing, emergency use or will soon be listed in COVID-19, and found that since 200211,oral drugs in COVID-19 have been on the scene continuously.
First of all, Merck's Monapivoxil and Huirui's Paciclovir were approved for marketing or emergency use. Then, China's original oral new drug VV 1 16 was recently approved for listing in Uzbekistan with excellent clinical trial data.
At present, COVID-19 oral drugs produced in Japan are also considered for listing in Japan. If this oral drug is approved for marketing, it will supply drugs to 1 10,000 people by the end of March, and it is planned to increase production in April to supply drugs to 1 10,000 people.
65438+1October 2 1, people wear masks and walk on the streets of Shibuya, Tokyo, Japan. According to Xinhua News Agency
COVID-19 Stomatology S-2 17622: It may be approved to be listed as early as spring.
This oral anti-COVID-19 drug named "S-2 17622" is currently undergoing a mid-term clinical trial. In its phase II and III clinical trials, compared with the control group taking placebo, the COVID-19 load of asymptomatic and mildly infected people who took drugs decreased by about 63% to 80% after 4 days. According to the company, this oral drug is also effective against the mutant Omicron strain in COVID-19.
Daimugong, president of Yanye Pharmaceutical Company, said, "The company will apply for the early listing of this oral drug as early as next week. Shionogi intends to add patients with moderate symptoms to the ongoing phase III trial and start the global clinical trial at the end of February. If this oral drug is approved for marketing, Yanyemu will be able to supply drugs to 65,438+0,000 people by the end of March, and it is planned to start in April. In the next fiscal year, the output will be greatly increased and drugs will be supplied to 6.5438+0 million people. "
COVID-19 stomatology VV 1 16: It is expected to be listed in China in the second half of this year.
The small molecule drug VV 1 16 for the treatment of COVID-19, which was jointly developed by Shanghai Institute of Pharmacology of China Academy of Sciences, Wuhan Institute of Virology of Chinese Academy of Sciences, Xinjiang Institute of Physical and Chemical Technology of Chinese Academy of Sciences and Central Asia Drug Research and Development Center of China Academy of Sciences, has entered the clinical trial stage in China.
According to CCTV news reports, preclinical pharmacodynamic studies show that VV 1 16 has significant inhibitory activity on the original and variant strains of COVID-19 virus, such as Delta virus. Researcher Shen Jingshan of Shanghai Institute of Pharmacology, China Academy of Sciences and cooperative scientific research institutions found that oral administration of VV 1 16 can reduce the virus titer below the detection limit and significantly improve the pathological changes of lung tissue in experimental model animals. A series of pre-clinical safety evaluation experiments show that VV 1 16 is safe and has no genotoxicity.
Small molecule drug VV 1 16 is being listed in China (the second half of the year is expected). Previously, the drug had been approved for emergency use in Uzbekistan.
Two oral drugs from COVID-19 have been approved for use in the United States.
19 On February 23rd, according to the US Food and Drug Administration (FDA), the FDA authorized the antiviral drug Molnupiravir to treat coronavirus pneumonia-19; In addition, on February 22nd, 19, the US FDA authorized Pfizer's coronavirus pneumonia-19 antiviral drug paciclovir, which is the first antiviral coronavirus pneumonia-19 pill in the United States, and can be taken at home before patients get sick.
Both drugs can reduce the risk of hospitalization and death of people who are diagnosed with coronavirus pneumonia-19 virus and may have serious diseases. Recent preclinical evidence shows that monapivvir has antiviral activity against Omicron. Paxlovid has an effective rate of 89% in preventing hospitalization and death of critically ill and high-risk patients.
In addition to the United States, the Israeli Ministry of Health issued a statement on February 26, 202 1 65438, saying that it had approved the emergency use of the oral drug paciclovir produced in Pfizer, USA, for the treatment of COVID-19.
Domestic specific drugs are approved orally, and two tablets can take effect. Since the outbreak of the COVID-19 epidemic in 2020, the global epidemic has lasted for more than two years, and the epidemic has continued to rage. From the original virus of the new crown to the mutant strain of Delta, and then to the mutant virus of Omicron, there is a long way to go to fight the epidemic. It is worth mentioning that according to the news in the newspaper, the first oral drug in COVID-19, VV 1 16, is expected to apply for listing in the second half of the year.
Heavy news from China.
Since the outbreak of the COVID-19 epidemic, our country has been fighting against the COVID-19 epidemic, taking extraordinary measures to deal with extraordinary events, controlling the spread of the virus in a short time, and handing over nearly perfect scores. China's COVID-19 vaccine is also in the forefront of the world, and the international community has high hopes for China.
At a time when China Kexing and Sinopharm vaccines have been accepted by the world, China announced great good news, that is, our COVID-19 small molecule oral new drug VV 1 16 has been approved to be listed in Uzbekistan. It is reported that compared with macromolecular drugs, small molecular oral drugs have more significant antiviral effect, lower production cost and medication cost, and are convenient for storage, transportation and transportation.
This specific medicine can take effect by taking two tablets orally. Does this mean that the COVID-19 epidemic is finally over? The use of small molecular oral drugs can quickly eliminate the virus and minimize the risk of virus transmission, which is more conducive to global epidemic prevention and control. COVID-19 oral drug developed by Chinese enterprises is another COVID-19 oral drug approved for marketing after Merck and Pfizer COVID-19 were approved.
Actively fighting the epidemic must not be taken lightly.
After the outbreak of the epidemic, China and Qi Xin joined forces to fight against COVID-19 and strive for an early victory in fighting the epidemic. However, in the face of global health crisis and epidemic diseases, it is far from enough to rely solely on China's efforts. All countries in the world should join the anti-epidemic team instead of emphasizing the so-called "group immunity".
At present, the United States is still the hardest hit area in the world, which proves that the "group immunity" advocated by western countries is not reliable and will only infect more people in COVID-19. The establishment of group immunity should be through reasonable channels, such as comprehensive vaccination of COVID-19 vaccine, rather than making antibodies in the body by infecting the virus, which is tantamount to making fun of human life.
In the face of the COVID-19 epidemic, no country can stay aloof. We hope that western countries can face up to the epidemic and learn from China's experience in fighting the epidemic, instead of letting it go and becoming COVID-19's "accomplice". If we don't work hard to fight the epidemic, it will be difficult to control the epidemic by developing more specific drugs.